Novel CD123-aptamer-originated targeted drug trains for selectively delivering cytotoxic agent to tumor cells in acute myeloid leukemia theranostics
Since conventional chemotherapy for acute myeloid leukemia (AML) has its limitations, a theranostic platform with targeted and efficient drug transport is in demand. In this study, we developed the first CD123 (AML tumor marker) aptamers and designed a novel CD123-aptamer-mediated targeted drug trai...
Saved in:
Main Authors: | Haibin Wu (Author), Meng Wang (Author), Bo Dai (Author), Yanmin Zhang (Author), Ying Yang (Author), Qiao Li (Author), Mingyue Duan (Author), Xi Zhang (Author), Xiaomei Wang (Author), Anmao Li (Author), Liyu Zhang (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2017-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A GD2-aptamer-mediated, self-assembling nanomedicine for targeted multiple treatments in neuroblastoma theranostics
by: Liyu Zhang, et al.
Published: (2021) -
Anti-CD123 antibody-modified niosomes for targeted delivery of daunorubicin against acute myeloid leukemia
by: Fu-rong Liu, et al.
Published: (2017) -
Radiolabelled Aptamers for Theranostic Treatment of Cancer
by: Umair Khalid, et al.
Published: (2018) -
Evaluation of the CD123 Expression and FLT3 Gene Mutations in Patients with Acute Myeloid Leukemia
by: Freidoon Solhjoo, et al.
Published: (2018) -
Novel CD123 polyaptamer hydrogel edited by Cas9/sgRNA for AML-targeted therapy
by: Haibin Wu, et al.
Published: (2021)